Alnylam Pharmaceuticals reported fourth quarter and full year 2025 financial results, achieving global net product revenues of $995 million for Q4 and $2,987 million for the full year, representing 121% and 81% growth compared to 2024, respectively, and attaining GAAP and non-GAAP profitability for the full year. The company also launched its 'Alnylam 2030' strategy and provided 2026 financial guidance.
Key takeaways
Achieved Q4 2025 global net product revenues of $995 million, representing 121% growth compared to Q4 2024
Achieved full year 2025 global net product revenues of $2,987 million, representing 81% growth compared to full year 2024
Attained GAAP and non-GAAP profitability for full year 2025
Launched 'Alnylam 2030' strategy focused on scaling through durable ATTR leadership, innovation, and financial results
Announced 2026 pipeline goals including 4 clinical readouts, 3 ongoing pivotal studies, 3 Phase 2 study initiations, and 3+ new IND filings
Reiterated net product sales guidance and provided additional 2026 financial guidance